CN105106210A - Composition 29080301030518 and an application thereof in preparation of antiviral medicine - Google Patents
Composition 29080301030518 and an application thereof in preparation of antiviral medicine Download PDFInfo
- Publication number
- CN105106210A CN105106210A CN201510565918.5A CN201510565918A CN105106210A CN 105106210 A CN105106210 A CN 105106210A CN 201510565918 A CN201510565918 A CN 201510565918A CN 105106210 A CN105106210 A CN 105106210A
- Authority
- CN
- China
- Prior art keywords
- virus
- compositions
- compound
- cell
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WBLXZSQLBOFHAB-UHFFFAOYSA-N CCCCCCNCCC Chemical compound CCCCCCNCCC WBLXZSQLBOFHAB-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the fields of organic synthesis and medicinal chemistry, and in particular relates to a composition 29080301030518 and an application thereof in preparation of an antiviral medicine. The invention discloses a composition 29080301030518 and a preparation method thereof. A pharmacological experiment proves that the composition 29080301030518 disclosed by the invention has an antiviral effect, and has the value of developing the antiviral medicine.
Description
Technical field
The present invention relates to organic synthesis and medicinal chemistry art, be specifically related to compositions 29080301030518, preparation method and its usage.
Background technology
Herpes simplex virus type 1 (Herpessimplexvirus, and herpes simplex virus type 2 (Herpessimplexvirus HSV-1), HSV-2) herpes coe virus is belonged to, HSV-1 and HSV-2 not only causes lip or genital mucosal herpes, is also cause encephalitis, hepatitis, the severe systemic infection even important pathogen of intrauterine infection simultaneously.
Respiratory syncytial virus (RespiratorySyncytialVirus, RSV) mainly causes respiratory system infection, causes serious pneumonia infant, old age and immunodeficiency crowd, is one of important pathogen of infecting of human upper respiratory tract.
Influenza A virus (InfluenzaAvirus, Flu-A) belongs to Orthomyxoviridae, has among a small circle every year popular, cause upper respiratory system to infect the mankind and other biological.When being very popular, serious respiratory system infection can be caused, notably cause pneumonia, encephalitis even dead.
There is the problem that toxicity is large, safety is low in above-mentioned three kinds of viral current existing medicines for the treatment of, from natural product, find compound or lead compound and carry out structural modification and obtain its derivant, thus the potential drug obtaining high-efficiency low-toxicity there is important value most.
The Compound I that the present invention relates to is one and delivers (MengShaoetal. in 2010, 2010.PsiguadialsAandB, TwoNovelMeroterpenoidswithUnusualSkeletonsfromtheLeaveso fPsidiumguajava.OrganicLetters12 (2010) 5040 – 5043) compound, we have carried out structural modification to Compound I, obtain two new derivants and compound III and compound IV, and prepared compositions 29080301030518 by compound III and compound IV, and said composition antiviral activity is evaluated, it has antiviral activity.
Summary of the invention
The invention discloses a new compositions 29080301030518, said composition is made up of compound III and compound IV, and in said composition, the mass percent of compound III and compound IV is respectively 40% and 60%.
Compositions disclosed by the invention can make pharmaceutically acceptable salt or pharmaceutically acceptable carrier.
Pharmacodynamic experiment shows, compositions of the present invention has good antivirus action.Pharmaceutically acceptable salt of the present invention has same drug effect.
The experiment in vitro of compositions shows, compositions has the activity of very strong anti-HSV-1, HSV-2, RSV and fluA, and therefore compositions of the present invention is expected to be used to prepare novel antiviral medicine.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation of embodiment 1 compound PsiguadialA
Document (the MengShaoetal. that the people such as the preparation method reference MengShao of compound PsiguadialA (I) deliver, 2010.PsiguadialsAandB, TwoNovelMeroterpenoidswithUnusualSkeletonsfromtheLeaveso fPsidiumguajava.OrganicLetters12 (2010) 5040 – 5043) method.
The synthesis of the O-bromoethyl derivant (II) of embodiment 2PsiguadialA
By Compound I (474mg, 1.00mmol) be dissolved in 20mL benzene, add in solution tetrabutyl ammonium bromide (TBAB) (0.16g), 1,50% sodium hydroxide solution of 2-Bromofume (7.520g, 40.00mmol) and 12mL.Mixture stirs 8h at 35 degrees Celsius.After 8h, reactant liquor is poured in frozen water, use dichloromethane extraction twice immediately, merge organic phase solution.Then use water and saturated common salt water washing 3 times successively to organic phase solution, then use anhydrous sodium sulfate drying, last concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:0.5, v/v), collects brown concentrated elution band and flings to the brown ceramic powder (502mg, 73%) that namely solvent obtains Compound II per.
1HNMR(500MHz,DMSO-d
6)δ10.44(s,2H),7.24(s,2H),7.20(d,J＝10.0Hz,3H),4.31(s,4H),3.89(s,1H),3.74(s,4H),2.30(s,1H),2.12(s,1H),2.02(s,1H),1.92(s,1H),1.79(s,1H),1.73(s,1H),1.51(d,J＝19.8Hz,3H),0.99(s,3H),0.95(d,J＝4.7Hz,7H),0.85(s,3H),0.53(s,1H),0.43(s,1H).
13CNMR(125MHz,DMSO-d6)δ188.69(s),170.54(s),165.42(s),163.38(s),142.72(s),129.71(s),127.96(s),127.08(s),118.00(s),116.82(s),114.82(s),72.73(s),40.19(s),34.75(s),34.32(s),31.75(s),30.93(s),28.09(s),26.43(s),24.48(s),23.74(s),21.18(s),20.77(s),19.99(s),14.39(s).
HRMS(ESI)m/z[M+H]
+calcdforC
34H
41Br
2O
5:689.1300；found689.1303.
The synthesis of O-(diethylin) ethyl derivative (III) of embodiment 3PsiguadialA
Compound II per (344mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, adds Anhydrous potassium carbonate (690mg wherein, 5.0mmol), potassium iodide (168mg, 1.0mmol) and diethylamine (2920mg, 40mmol), mixture reflux 9h.After reaction terminates, reactant liquor is poured in frozen water, with equivalent dichloromethane extraction 4 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.Product crude product purification by silica gel column chromatography (mobile phase is: petroleum ether/acetone=100:1.5, v/v), collects yellow concentrated elution band and flings to the yellow powder (231.8mg, 69%) that namely solvent obtains compound III.
1HNMR(500MHz,DMSO-d6)δ10.40(s,2H),7.20(s,2H),7.16(d,J＝10.0Hz,3H),4.01(s,4H),3.92(s,1H),2.80(s,8H),2.58(s,4H),2.07(s,1H),1.87(d,J＝8.4Hz,2H),1.77(s,1H),1.63(d,J＝16.8Hz,2H),1.46(s,1H),1.40(s,2H),1.21(s,1H),1.09(s,12H),0.92(s,3H),0.86(s,6H),0.83(s,3H),0.48(s,1H),0.22(s,1H).
13CNMR(125MHz,DMSO-d6)δ188.13(s),170.24(s),165.66(s),163.19(s),142.21(s),129.74(s),127.81(s),127.13(s),117.32(s),116.78(s),114.65(s),69.32(s),52.18(s),47.25(s),40.16(s),34.49(s),34.15(s),30.26(s),28.31(s),26.33(s),24.11(s),23.47(s),21.56(s),20.83(s),19.14(s),14.25(s),12.17(s).
HRMS(ESI):m/z[M+H]
+calcdforC
42H
61N
2O
5:673.4580；found:673.4576。
The synthesis of O-(piperidyl) ethyl derivative (IV) of embodiment 4PsiguadialA
Compound II per (344mg, 0.5mmol) is dissolved in the middle of 20mL acetonitrile, adds Anhydrous potassium carbonate (690mg wherein, 5.0mmol), potassium iodide (168mg, 1.0mmol) and piperidines (1704mg, 20mmol), mixture reflux 10h.After reaction terminates, reactant liquor is poured in 25mL frozen water, with equivalent dichloromethane extraction 4 times, merge organic facies.Organic facies after merging with water and saturated common salt water washing successively, then use anhydrous sodium sulfate drying, concentrating under reduced pressure is removed solvent and is obtained product crude product.(mobile phase is product crude product purification by silica gel column chromatography: petroleum ether/acetone=100:1.0, v/v), collect the yellow yellow gummy solid (212.3mg, 61%) concentrating elution band namely to obtain O-(piperidyl) ethyl derivative (IV) of Cleistanone.
1HNMR(500MHz,DMSO-d6)δ10.58(s,2H),7.36(s,2H),7.30(d,J＝10.0Hz,3H),4.20(s,1H),4.12(s,4H),2.68(s,4H),2.51(s,8H),2.34(s,1H),2.06(d,J＝9.1Hz,2H),1.99(d,J＝5.5Hz,2H),1.75(s,1H),1.57(d,J＝8.5Hz,10H),1.51(s,1H),1.45(d,J＝8.0Hz,5H),1.07(s,3H),1.01(s,6H),0.99(s,3H),0.65(s,1H),0.35(s,1H).
13CNMR(125MHz,DMSO-d6)δ188.11(s),170.25(s),165.46(s),163.73(s),142.84(s),129.97(s),127.32(s),127.54(s),117.68(s),116.17(s),114.32(s),69.59(s),54.43(d,J＝16.3Hz),40.76(s),34.92(s),34.84(s),30.65(s),28.33(s),26.21(s),24.37(d,J＝10.4Hz),23.88(s),23.41(s),21.97(s),20.48(s),19.26(s),14.11(s).
HRMS(ESI):m/z[M+H]
+calcdforC
44H
61N
2O
5:697.4580；found:697.4576。
Embodiment 5 compositions antiviral activity
(1) experimental example: compositions is to the Effect study of herpesvirus:
(1) cell strain and Strain:
HEKC (HEK293 is HSV-1, HSV-2 virus sensitive cells) purchased from American Clontech company; Herpes simplex virus type 1 (HSV-1) Sm44 strain, simple herpes virus 2 type (HSV-2) 333 strain are drawn from Chinese CDC virosis institute.
(2) cytotoxic assay:
The preparation of compositions 29080301030518: the powder of the powder of 40mg compound III and 60mg compound IV is loaded to mix in tubule with cover and with turbine stirring instrument and namely obtain 100mg compositions 29080301030518.
Reference literature (Wang Shouchuan, Wang Lin, old superfine, oral liquid for clearing away lung-heat Contained Serum to the experimentation of viral inhibition, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25 ~ 27) method, does serial dilution (2 by each sample with 2 multiple proportions
0 ~-5), then be inoculated on the HEK293 in 96 plate holes by dilution sequential lateral, every hole 100uL, every dilution factor longitudinally repeats 3 holes (A, B, C are capable), parallel 1 ~ 6 hole of microwell plate D of setting is as cell controls, 7 ~ 12 holes not inoculating cell are blank, microscope observes CPE lower every day, Continuous Observation 7d, neutral red staining, measure OD value at 540nm wavelength, by experimental group calculating cell survival rate compared with cell controls group OD value, calculate medicine half cytotoxic concentration (TD by Reed-Muench method
50).
(4) toxin inhibitory test:
Reference literature (Wang Shouchuan, Wang Lin, old superfine, oral liquid for clearing away lung-heat Contained Serum to the experimentation of viral inhibition, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25 ~ 27) method, by sample by dilution order (2
-3 ~-14) be laterally inoculated in 96 plate holes cell monolayer on, every hole 100uL, every dilution factor longitudinally repeats 4 holes, and A, B, C of microwell plate are capable to be added containing 100 TCID
50viral 100uL as test group, capable the supplementing of D waits capacity cell maintenance medium to be variable concentrations drug control, and the parallel F that establishes is capable of virus control, E capable 1 ~ 12 as cell controls.37 DEG C, 5%CO
2cultivate, every day observes CPE, Continuous Observation 4d.When there is more than 90% CPE in virus control, add 1% neutral red staining, A value is read at wavelength 540nm wavelength by microplate reader, each group of A value removes virus control group A value, by each test group compared with cell controls group A value, obtain cell survival rate, calculate half by Reed-Muench method and press down malicious concentration (IC
50), TD the most at last
50and IC
50compare to obtain and press down malicious index (TI).
(5) result:
1. sample TD
50mensuration: cellular control unit basis of microscopic observation adherent growth is fine and close, form is good.The TD of compositions 29080301030518, compound III and compound IV
502 are respectively at HEK293
-1.17, 2
-2.04, 2
-2.65.
2. poison experiment is pressed down: the adherent densification of cellular control unit, form are good.Microscopic observation finds, the CPE of more than 90% is there is respectively in HSV-1, HSV-2 virus control group at 3d, 3d, HSV1 with HSV2 HEK293CPE then with swelling, many cells merge (HSV1 cause multiple cell warm become bulla, and HSV2 cause be fused to vesicle), become circle, come off into principal character.
And compositions 29080301030518 toxin inhibitory test respectively organizes cell; according to compositions 29080301030518 diluted sample gradient; gradient rule occur CPE:HSV1-HEK293 before the 10th dilution factor, HSV2-HEK293 group cell before the 9th dilution factor is completely protected; occur CPE afterwards, CPE reduces with sample concentration and increases the weight of gradually.
And compound III and compound IV processed group are 2
-4 ~-6the effect suppressing virus is just observed in concentration range.
By above-mentioned brassboard 1% neutral red staining, survey 450nmA value by microplate reader, after each group A value cuts virus control group A value, each experimental group A value obtains IC compared with cell controls group A value
50, IC
50with TD
50compare the TI obtaining compositions 29080301030518: suppress HSV-1, HSV-2, at HEK293 cell, CPE, IC occur
50be respectively 2
-12.76, 2
-12.02, TI is respectively 3082.7,1845.8.The TI of compound III: corresponding IC
50be respectively 2
-4.11, 2
-5.03, TI is respectively 4.2,7.9.The TI of compound IV: corresponding IC
50be respectively 2
-4.58, 2
-4.11, TI is respectively 3.8,2.8.
Conclusion: compositions 29080301030518 has the effect of significant herpes coe virus (comprising HSV-1, HEV-2), and safety is high, therefore compositions 29080301030518 has a wide range of applications background in treatment herpesvirus infection disease.Compound III and compound IV do not have the effect of significant herpes coe virus (comprising HSV-1, HEV-2), and safety is extremely low, and therefore compound III and compound IV do not have application background in treatment herpesvirus infection disease.
(2) experimental example: compositions is to the Effect study of respiratory syncytial virus (RSV)
(1) configuration of compositions 29080301030518, compound III and compound IV: medicine is dissolved in cell maintenance medium (containing the MEM of 2% new-born calf serum, GIBICO Products) for subsequent use.
(2) cell strain and Strain:
HEKC (HEK293, RSV virus sensitive cells) purchased from American Clontech company; Respiratory syncytial virus (RSV) Long strain is drawn from Chinese CDC virosis institute.
(3) cytotoxic assay:
Reference literature (Wang Shouchuan, Wang Lin, old superfine, oral liquid for clearing away lung-heat Contained Serum to the inhibiting experimentation of respiratory syncytial virus, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25 ~ 27) method, does serial dilution (2 by sample with 2 multiple proportions
0 ~-5), then be inoculated on the HEK293 in 96 plate holes by dilution sequential lateral, every hole 100uL, every dilution factor longitudinally repeats 3 holes (A, B, C are capable), parallel 1 ~ 6 hole of microwell plate D of setting is as cell controls, 7 ~ 12 holes not inoculating cell are blank, microscope observes CPE lower every day, Continuous Observation 7d, neutral red staining, measure OD value at 540nm wavelength, by experimental group calculating cell survival rate compared with cell controls group OD value, calculate medicine half cytotoxic concentration (TD by Reed-Muench method
50).
(4) toxin inhibitory test:
Reference literature (Wang Shouchuan, Wang Lin, old superfine, oral liquid for clearing away lung-heat Contained Serum to the inhibiting experimentation of respiratory syncytial virus, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25 ~ 27) method, by sample by dilution order (2
-2 ~-13) be laterally inoculated in 96 plate holes cell monolayer on, every hole 100uL, every dilution factor longitudinally repeats 4 holes, and A, B, C of microwell plate are capable to be added containing 100 TCID
50viral 100uL as test group, capable the supplementing of D waits capacity cell maintenance medium to be variable concentrations drug control, and the parallel F that establishes is capable of virus control, E capable 1 ~ 12 as cell controls.37 DEG C, 5%CO
2cultivate, every day observes CPE, Continuous Observation 4d.When there is more than 90% CPE in virus control, add 1% neutral red staining, A value is read at wavelength 540nm wavelength by microplate reader, each group of A value removes virus control group A value, by each test group compared with cell controls group A value, obtain cell survival rate, calculate half by Reed-Muench method and press down malicious concentration (IC
50), TD the most at last
50and IC
50compare to obtain and press down malicious index (TI).
(5) result:
1. sample TD
50mensuration: cellular control unit basis of microscopic observation adherent growth is fine and close, form is good.Compositions 29080301030518, compound III and compound IV are to the TD of HEK293
50be respectively 2
-2.19, 2
-2.78, 2
-2.95.
2. poison experiment is pressed down: the adherent densification of cellular control unit, form are good.Microscopic observation finds, RSV virus control group occurs the CPE of more than 90% at 2d, and RSV strengthens with refractivity at HEK293CPE, change is justified, comes off, is broken for principal character.
And compositions 29080301030518 toxin inhibitory test respectively organizes cell, according to diluted sample gradient, there is CPE in gradient rule:
RSV-HEK293 test group cell is before the 9th dilution factor, and cell is completely protected, occurs CPE afterwards, and CPE reduces with sample concentration and increases the weight of gradually.
And compound III and compound IV processed group are 2
-4 ~-6the effect suppressing virus is just observed in concentration range.
By above-mentioned brassboard 1% neutral red staining, survey 450nmA value by microplate reader, after each group A value cuts virus control group A value, each experimental group A value obtains IC compared with cell controls group A value
50, IC
50with TD
50compare and obtain TI: compositions 29080301030518 suppresses RSV, at HEK293 cell, CPE, IC occur
50be 2
-11.99, TI is 891.4; The IC of compound III
50be 2
-4.13, TI is 2.5; The IC of compound IV
50be 2
-5.73, TI is 6.9.
Conclusion: compositions 29080301030518 has the effect that significant anti-pair glues coe virus respiratory syncytial virus RSV, can be used for preparing anti-pair and glue coe virus respiratory syncytial virus RSV medicine.Compound III and compound IV glue the effect of coe virus respiratory syncytial virus RSV without significant anti-pair, are not available to prepare anti-pair and glue coe virus respiratory syncytial virus RSV medicine.
(3) experimental example: compositions is to the Effect study of influenza A virus:
(1) cell strain and Strain: Madin-Darby canine kidney(cell line) (MDCK) (MDCK, influenza virus sensitive cells) is drawn from Chinese CDC virosis institute; Influenza virus A type (FluA) 1995.AII:32094 strains draws from Chinese CDC virosis institute.
(2) cytotoxic assay:
Reference literature (Wang Shouchuan, Wang Lin, old superfine, oral liquid for clearing away lung-heat Contained Serum to the experimentation of viral inhibition, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25 ~ 27) method, does serial dilution (2 by each sample with 2 multiple proportions
-1 ~-5), then be inoculated on the MDCK in 96 plate holes by dilution sequential lateral, every hole 100uL, every dilution factor longitudinally repeats 3 holes (A, B, C are capable), parallel 1 ~ 6 hole of microwell plate D of setting is as cell controls, 7 ~ 12 holes not inoculating cell are blank, microscope observes CPE lower every day, Continuous Observation 7d, neutral red staining, measure OD value at 540nm wavelength, by experimental group calculating cell survival rate compared with cell controls group OD value, calculate medicine half cytotoxic concentration (TD by Reed-Muench method
50).
(3) toxin inhibitory test:
Reference literature (Wang Shouchuan, Wang Lin, old superfine, oral liquid for clearing away lung-heat Contained Serum to the experimentation of viral inhibition, Nanjing University of Traditional Chinese Medicine's journal, 2008; 24 (1): 25 ~ 27) method, be inoculated on the cell monolayer in 96 plate holes by sample by dilution sequential lateral, every hole 100uL, every dilution factor longitudinally repeats 4 holes, and A, B, C of microwell plate are capable to be added containing 100 TCID
50viral 100uL as test group, capable the supplementing of D waits capacity cell maintenance medium to be variable concentrations drug control, and the parallel F that establishes is capable of virus control, E capable 1 ~ 12 as cell controls.37 DEG C, 5%CO
2cultivate, every day observes CPE, Continuous Observation 4d.When there is more than 90% CPE in virus control, add 1% neutral red staining, A value is read at wavelength 540nm wavelength by microplate reader, each group of A value removes virus control group A value, by each test group compared with cell controls group A value, obtain cell survival rate, calculate half by Reed-Muench method and press down malicious concentration (IC
50), TD the most at last
50and IC
50compare to obtain and press down malicious index (TI).
(4) result:
1. sample TD
50mensuration: cellular control unit basis of microscopic observation adherent growth is fine and close, form is good.The TD that compositions 29080301030518, compound III and compound IV are right
502 are respectively at MDCK
-2.18, 2
-2.09, 2
-2.68.
2. poison experiment is pressed down: the adherent densification of cellular control unit, form are good.Microscopic observation finds, FluA strengthens with refractivity at MDCKCPE, downright bad, be broken for principal character.
And compositions 29080301030518 toxin inhibitory test respectively organizes cell, according to diluted sample gradient, gradient rule occurs that CPE:FluA-MDCK group cell cell before the 8th dilution factor is completely protected, occurs CPE afterwards, and CPE reduces with sample concentration and increases the weight of gradually.
And compound III and compound IV processed group are 2
-4 ~-6the effect suppressing virus is just observed in concentration range.
By above-mentioned brassboard 1% neutral red staining, the A value surveying 450nm by microplate reader, after each group A value cuts virus control group A value, each experimental group A value obtains IC compared with cell controls group A value
50, IC
50with TD
50compare and obtain TI: compositions 29080301030518 suppresses FluA, at mdck cell, CPE occurs, IC
50be 2
-11.33, TI is 568.1; The IC of compound III
50be 2
-4.95, TI is 7.3; The IC of compound IV
50be 2
-3.98, TI is 2.5.
Conclusion: compositions 29080301030518 pairs of influenza A viruss have very strong inhibitory action, and safety, therefore compositions 29080301030518 has a wide range of applications background in treatment influenza a virus infection disease.Compound III and compound IV do not have significant inhibitory action to influenza A virus, and safety is extremely low, and therefore compound III and compound IV do not have application background in treatment influenza a virus infection disease.
The preparation of embodiment 6 compositions 29080301030518 involved in the present invention tablet
Get 2 grams of compositionss 29080301030518, add the customary adjuvant 18 grams preparing tablet, mixing, conventional tablet presses makes 100.
The preparation of embodiment 7 compositions 29080301030518 involved in the present invention capsule
Get 2 grams of compositionss 29080301030518, add prepare capsule customary adjuvant as starch 18 grams, mixing, encapsulatedly makes 100.
Claims (9)
1. a compositions 29080301030518, it is characterized by said composition and be made up of compound III and compound IV, in said composition, the mass percent of compound III and compound IV is respectively 40% and 60%.
2. the preparation method of compositions 29080301030518 as claimed in claim 1, is characterized by: the powder of compound III and the powder of compound IV are respectively 40% and 60% according to mass percent and fully mix.
3. the application of a compositions 29080301030518 as claimed in claim 1 in antiviral drugs.
4. the application of compositions 29080301030518 in antiviral drugs as claimed in claim 3, is characterized in that: described virus is influenza A virus.
5. the application of compositions 29080301030518 in antiviral drugs as claimed in claim 3, is characterized in that: described virus is herpes simplex virus.
6. the application of compositions 29080301030518 in antiviral drugs as claimed in claim 3, is characterized in that: described virus is respiratory syncytial virus.
7. the application of compositions 29080301030518 in antiviral drugs as claimed in claim 5, is characterized in that: described herpes simplex virus is herpes simplex virus type 1 or simple herpes virus 2 type.
8. the application of compositions 29080301030518 in antiviral drugs as claimed in claim 7, is characterized in that: described herpes simplex virus type 1 is the Sm44 strain of herpes simplex virus type 1.
9. the application of compositions 29080301030518 in antiviral drugs as claimed in claim 7, is characterized in that: described herpes simplex virus type 2 is the strain of simple herpes virus 2 type 333.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510565918.5A CN105106210A (en) | 2015-09-08 | 2015-09-08 | Composition 29080301030518 and an application thereof in preparation of antiviral medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510565918.5A CN105106210A (en) | 2015-09-08 | 2015-09-08 | Composition 29080301030518 and an application thereof in preparation of antiviral medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105106210A true CN105106210A (en) | 2015-12-02 |
Family
ID=54654493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510565918.5A Pending CN105106210A (en) | 2015-09-08 | 2015-09-08 | Composition 29080301030518 and an application thereof in preparation of antiviral medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105106210A (en) |
-
2015
- 2015-09-08 CN CN201510565918.5A patent/CN105106210A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 万春杰 等.: "过氧化物酶体增殖剂活化受体γ激动剂在支气管哮喘和呼吸道合胞病毒感染中的作用研究", 《中华哮喘杂志（电子版）》 * |
| 蒋利荣 等.: "番石榴叶中二醛杂源萜类化学成分研究", 《广州化工》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108473477A (en) | The pyrimidine of aryl substitution for being used in influenza infection | |
| CN104130307B (en) | Close O-(Pyrrolidine base) ethyl derivative, the preparation method and its usage of flowers and trees ketone Cleistanone | |
| CN104086612A (en) | 4-substituted amido-2'-deoxo-2'-fluoro-4'-azido-beta-D-cytidine compounds and preparation method and application thereof | |
| CN105232510A (en) | Composition and application thereof to antiviral drugs | |
| CN105106210A (en) | Composition 29080301030518 and an application thereof in preparation of antiviral medicine | |
| CN104083380B (en) | The application in preparation antiviral drugs of the dimethylamine derivative of Cleistanone Cleistanone | |
| CN105343106A (en) | Composition and application thereof in antiviral agents | |
| CN105250290A (en) | Composition and application thereof to antiviral medicines | |
| CN105343087A (en) | Composition and application thereof in antiviral drugs | |
| CN104825465A (en) | Application of O-(1H-tetrazol)ethyl derivative of Cleistanone in preparation of antiviral drugs | |
| CN105232536A (en) | Composition and application thereof in antiviral drugs | |
| CN105412115A (en) | Composition and application of composition in antiviral medicine | |
| CN105125550A (en) | Composition and application thereof in antiviral drugs | |
| CN105287571A (en) | Composition and application thereof to antiviral medicines | |
| CN105287458A (en) | Composition and application thereof to antiviral medicines | |
| CN105343078A (en) | Composition and application of composition in preparation of antiviral medicines | |
| CN104922119A (en) | Application of O-(diethylin) ethyl derivative of Daphmalenine A to preparation of antiviral drug | |
| CN104800212A (en) | Application of Daphmalenine A derivative in preparing antiviral drug | |
| CN104188981B (en) | The application in preparation antiviral drugs of O-(morpholinyl) ethyl derivative of Cleistanone Cleistanone | |
| CN105343065A (en) | Composition and application of composition to preparation of antiviral medicines | |
| CN106074527A (en) | The compositions of Schiglautone A derivant is used for preparing antiviral drugs | |
| CN105998006A (en) | Application of composition of Salviskinone A benzimidazolyl and di(2-methylmercapto ethyl)amido derivatives in antiviral drugs | |
| CN106074523A (en) | The application in antiviral drugs of the compositions of O (benzimidazolyl) ethyl of Artalbic acid and O (two hydroxyethylamines) ethyl derivative | |
| CN106074530A (en) | The composition of Ah draw'sing Bick acid triazolyl and 1H tetrazole radical derivative is for preparing antiviral drugs | |
| CN105853425A (en) | Application of composition of piperazinyl and imidazolyl derivatives of Virosaine A in antiviral drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151202 |